Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 inhibitors combined with chemotherapy, have become the front-line standard of care for extensive-stage small cell lung cancer (SCLC). This evidence concerns the gene CD274 and small cell lung carcinoma.